{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04169321",
            "orgStudyIdInfo": {
                "id": "2019-hGZP-101.12"
            },
            "organization": {
                "fullName": "Cytosite Biopharma Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors",
            "officialTitle": "First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "granzyme-b-pet-imaging-drug-as-a-predictor-of-immunotherapy-response-to-checkpoint-inhibitors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-06-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-11-04",
            "studyFirstSubmitQcDate": "2019-11-18",
            "studyFirstPostDateStruct": {
                "date": "2019-11-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cytosite Biopharma Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Massachusetts General Hospital",
                    "class": "OTHER"
                },
                {
                    "name": "University of Alabama at Birmingham",
                    "class": "OTHER"
                },
                {
                    "name": "Chang Gung Memorial Hospital",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "First in Human Safety of \\[68Ga\\]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy",
            "detailedDescription": "This is a first in human research study (Phase I clinical trial) to test the safety and effectiveness of a new radioactive PET imaging drug and biomarker \\[68Ga\\]-NOTA-hGZP. It is a multi-center, open label, non-randomized, two dose study to evaluate the safety of \\[68Ga\\]-NOTA-hGZP and the ability to predict the clinical response to checkpoint inhibitor therapy within 2 cycles of treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Unspecified, Adult",
                "Lymphoma"
            ],
            "keywords": [
                "cancer immunotherapy",
                "biomarkers, tumor",
                "positron-emission tomography",
                "Granzymes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Multiple center, open label, non-randomized, single dose study, in subjects with cancer undergoing or treatment with a checkpoint inhibitor either as a monotherapy or in combination. subjects. Eligible subjects will receive an injection of \\[68Ga\\]-NOTA-hGZP pre checkpoint inhibitor administration and a second dose between 5 and 42 days post initial checkpoint inhibitor administration. Upon dosing each subject will undergo PET scans at 40, 60 and 90 minutes post dosing. The images will be analyzed for the distribution of radioactivity. Subjects will be followed for adverse events for approximately 4-6 hours post injection or until pembrolizumab injection plus a follow up phone call to assess adverse events 1-3 days after injection.",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single Arm",
                    "type": "EXPERIMENTAL",
                    "description": "All participants will receive a mass dose of 40 \u03bcg or less of \\[68Ga\\]-NOTA-hGZP (radioactivity dose of 3 mCi to 8 mCi) and have a PET and CT scan.",
                    "interventionNames": [
                        "Drug: Single Arm"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Single Arm",
                    "description": "\\[68Ga\\]-NOTA-hGZP is a PET imaging agent.",
                    "armGroupLabels": [
                        "Single Arm"
                    ],
                    "otherNames": [
                        "[68Ga]-NOTA-hGZP",
                        "CSB-111"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with clinically meaningful changes in physical examination findings, vital signs or blood chemistry",
                    "description": "Clinically significant changes from baseline in physical examination findings\n\nClinically significant changes from baseline to follow-up analysis in systolic and diastolic blood pressure (mmHg)\n\nClinically significant changes from baseline to follow-up analysis in heart rate (beats per minute)\n\nClinically significant changes in respiration rate.\n\nClinically significant changes from baseline to follow-up analysis in blood chemistry for:\n\n1. Leukocytes (/mcL),\n2. Absolute neutrophil count (mcL)\n3. Platelets (/mcL)\n4. Total bilirubin (mg/d)\n5. AST/ALT (unitless)\n6. Albumin (g/dL)\n7. Alkaline phosphatase (IU/L)\n8. eGRF (mL/min/1.73 m2)",
                    "timeFrame": "up to 4 to 6 hours post-injection"
                },
                {
                    "measure": "Number of participants with changes in ECG",
                    "description": "Clinically significant changes from baseline to follow-up analysis in ECG change in QT (ms) Quantification of \\[68Ga\\]-NOTA-hGZP PET accumulation at tumor site in subjects after treatment with checkpoint inhibitor therapy as determined by region of interest analysis (SUVmean).",
                    "timeFrame": "up to 4 to 6 hours post-injection"
                },
                {
                    "measure": "Number of participants with treatment-related Adverse Events (AEs)",
                    "description": "The absolute number of participants with AEs according to CTCAE 5.0",
                    "timeFrame": "Between time of injection and 3 days post injection"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of the accumulation of [68Ga]-NOTA-hGZP in tumor foci in participants receiving checkpoint inhibitor therapy (absolute number of avid lesions per subject)",
                    "description": "Identification by the central reader of the number of avid lesions observed in each subject and the number of subjects with avid lesions seen on the PET images",
                    "timeFrame": "up to one-hour post injection"
                },
                {
                    "measure": "Quantification of accumulation of [68Ga]-NOTA-hGZP in tumor foci in participants receiving checkpoint inhibitor therapy.",
                    "description": "To be determined by region of interest analysis the mean standardized uptake value (SUVmean) (SUV does not have any units)",
                    "timeFrame": "up to one-hour post injection"
                },
                {
                    "measure": "Evaluate the correlation of [68Ga]-NOTA-hGZP accumulation in tumor foci to 6-month outcome.",
                    "description": "Compare quantified \\[68Ga\\]-NOTA-hGZP uptake to participant treatment response in individual lesions as assessed at 6-month clinical follow-up and/or CT assessments.\n\nThe number of lesions that were avid and the lesions that showed a decrease in size compared to those which increased in size.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Correlate uptake of [68Ga]-NOTA-hGZP tracer and granzyme B expression as assessed on optional excisional biopsy when available (melanoma only).",
                    "description": "Compare granzyme B protein quantification from biopsied tissue to the \\[68Ga\\]-NOTA-hGZP PET uptake acquired at the same location.",
                    "timeFrame": "up to one-hour post injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects 18 years of age and older.\n2. Subjects with proven metastatic cancer that is going to be treated with one or more checkpoint inhibitors under the licensed indications for the cancer type. Checkpoint inhibitors include PD-1, PD-L1, CTLA-4 and LAG-3 inhibitors.\n3. Subjects must have at least one lesion \u2265 15 mm in diameter or with two lesions both \u2265 15mm in diameter, when an optional biopsy is planned. Lesion measurements are taken from a diagnostic quality CT or MR image.\n4. ECOG performance status \u2264 2 (Karnofsky \u2265 60%)\n5. Life expectancy of greater than 6 months.\n6. Males and females willing to use adequate contraception prior to study and during study participation.\n7. If female, not of childbearing potential or negative pregnancy test prior to radiotracer injection.\n8. Willing and able to understand and sign a written informed consent document.\n9. Willing and able to undergo all study procedures.\n10. Cohort 3 only: have archival lesion tissue available within 90 days of enrollment either from biopsy or surgery.\n\nExclusion Criteria:\n\n1. Participants for whom adverse events due to agents administered more than 4 weeks earlier have not resolved to Grade 1 or less.\n2. Has not received nor is expected to receive an investigational compound within 90 days prior to \\[68Ga\\]-NOTA-hGZP PET imaging. This includes checkpoint inhibitors that are not approved by the US FDA for the indications in this protocol.\n3. Subjects who have received a prior checkpoint inhibitor.\n4. Any acute or chronic inflammatory disease or medical conditions that in the investigator's opinion may interfere with the study procedures or the interpretation of the study results such as infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.\n5. Known brain metastases.\n6. History of allergic reactions to compounds of similar chemical or biologic composition to \\[68Ga\\]-NOTA-hGZP or pembrolizumab.\n7. If female, nursing.\n8. Current treatment with systemic steroids, or immunosuppressive agents. Participants with a condition requiring systemic treatment with either corticosteroids (\\< 10 mg daily prednisone equivalent) inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n9. Subjects who have exclusion criteria that would prevent them from receiving a CT scan.\n10. Laboratory values\n\n    1. Leukocytes \\< 3000/mcL\n    2. Absolute neutrophil count \\< 1500 mcL\n    3. Platelets \\< 100,000 mCL\n    4. Total bilirubin \\> 1.5 x ULN\n    5. AST/ALT \\> 2.5 x ULN\n    6. Albumin \\< 2 g/dL\n    7. Alkaline phosphatase \\> 2.5 ULN\n    8. eGRF eGFR \\< 45 mL/min/1.73 m2\n\nPatients who are stable but have values outside the specified ranges may be included with approval of the study medical monitor.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Colin G Miller, PhD",
                    "role": "CONTACT",
                    "phone": "2679182806",
                    "email": "cmiller@cytositebio.com"
                },
                {
                    "name": "Lieselotte Bloss, DVM",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Colin G Miller, PhD",
                    "affiliation": "CytoSite Bio Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "COMPLETED",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "COMPLETED",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Chang-Gung Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Taoyuan City",
                    "state": "Guishan",
                    "zip": "333",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Chihhsi Kuo, MD",
                            "role": "CONTACT",
                            "phone": "886 3 3281200",
                            "email": "chihhsikuo@gmail.com"
                        },
                        {
                            "name": "Little Ho, MD",
                            "role": "CONTACT",
                            "phone": "886 3 3281200",
                            "email": "b8301068@gmail.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}